Mylan launched its Omeprazole products on August 4, 2003, despite the patent infringement litigation, which at the time was unprecedented in the generic pharmaceutical industry.
Robert Coury, vice chairman and CEO of Mylan, said: “Our original decision to launch this product means that consumers, the government and third-party payors have benefited significantly for nearly five years because they’ve had access to a lower-cost generic version of Prilosec.”